Shots: The P-III study assessing Kevzara (400mg) + BSC vs BSC in 194 patients with COVID-19 requiring mechanical ventilation did not meet it’s 1EPs & 2EPs Based on the results, […]readmore
Tags : Kevzara
Shots: Following the IDMC recommendation, ongoing P-III study will be amended to enroll only critical patients. The P-III study also be amended discontinue lower-dose of Kevzara (200 mg) with all […]readmore
Shots: The first patient has been treated as a part of the global clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19. The P-II/III clinical program has initiated […]readmore
Shots: The P-II/III study will assess the safety & efficacy Kevzara + supportive care vs PBO + supportive care in ~400 patients in a ratio (2:2:1) hospitalized with serious complications […]readmore
Shots: Sanofi and Regeneron will simplify their Ab collaboration for Kevzara and Praluent by restructuring into a royalty-based agreement Under the proposed restructuring, Sanofi is expected to get WW rights […]readmore